Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXC-201 in BCMA-Expressing Multiple Myeloma and AL Amyloidosis
NCT04720313Phase 1Active, not recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- Jan 2021
- Primary completion
- Jan 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of NP-201 in multiple myeloma (MM) and amyloid light chain amyloidosis, sponsored by Hadassah Medical Organization. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Jan 2021; status: active, not recruiting.
02
Drugs
NP-201
03
Conditions
multiple myeloma (MM)amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT04720313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720313.